Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PHGDH | O43175 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562908 | 0.89 | PHGDH (0.45) | LMNAALDH1A1SMN1; SMN2PHGDHMAPT | |
| SCHEMBL6559720 | 0.87 | MAPT (0.39) | LMNAALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6657804 | 0.81 | SMN1; SMN2 (0.46) | LMNAALDH1A1SMN1; SMN2PHGDHMAPT | |
| SCHEMBL6657915 | 0.80 | SMN1; SMN2 (0.52) | LMNAALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6561276 | 0.80 | KMT2A (0.52) | LMNAALDH1A1SMN1; SMN2PHGDHKMT2A | |
| SCHEMBL6560550 | 0.79 | PHGDH (0.47) | ALDH1A1PHGDHMAPTRECQLKMT2A | |
| SCHEMBL6559736 | 0.79 | PHGDH (0.62) | LMNAALDH1A1PHGDHKMT2AMEN1 | |
| SCHEMBL6560754 | 0.77 | PHGDH (0.58) | LMNAALDH1A1PHGDHKMT2AMEN1 | |
| SCHEMBL6560843 | 0.77 | MAPT (0.42) | LMNAALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6559686 | 0.76 | PHGDH (0.57) | LMNAALDH1A1SMN1; SMN2PHGDHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1075469-B1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARM CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | LMNA 3343/4885ALDH1A1 58/4885SMN1; SMN2 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.